Alto Neuroscience

failure crash no fail rocket cancelled end

Alto's midphase depression trial falls flat

A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary endpoints, wiping 60% off the biotech’s share price.

Nick Paul Taylor Oct 23, 2024 4:47am

CRISPR Tx, Novartis, Cour & more—Chutes & Ladders

May 24, 2024 8:30am

Graphic of an open door with the words exit above it

Biogen CMO heads for the exits

Mar 15, 2024 10:51am

Wall Street IPO initial public offering markets shares stock

Alto, Fractyl head to public markets with IPOs north of $100M

Feb 2, 2024 8:14am

Photo of Wall Street street sign with american flags in the background

Alto aims for $101M IPO to pave neuro development climb

Jan 30, 2024 11:37am

Alto Neuroscience preps IPO to push CNS therapies through clinic

Jan 16, 2024 6:51am